dm+d

Unassigned

New Medicines

Non-alcoholic steatohepatitis (NASH) with stage 4 liver fibrosis (cirrhosis)

Information

New molecular entity
Galectin Therapeutics
Galectin Therapeutics

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

A small-molecule galectin-3 inhibitor , given by infusion every other week
NASH is a serious liver disease resulting from metabolic dysfunction that is associated with steatosis (fat within the liver), inflammation and fibrosis, which may progress to cirrhosis. NASH-related cirrhosis is expected to become the leading indication for liver transplantation by 2020 [1].
Non-alcoholic steatohepatitis (NASH) with stage 4 liver fibrosis (cirrhosis)
Bladder instillation